Classical and "non-classical" cardiovascular risk factors in Tunisian patients with end stage renal disease: Prevalence and association with cardiovascular events

Clinical Laboratory

Volumn 50, Issue 7-8, 2004, Pages 447-453

  Fellah, Hayet ^a   Feki, Moncef ^a   Feki, Habib ^b   Souissi, Malek ^a   Kaabachi, Neziha ^a   Abdallah, Taieb Ben ^c   Massy, Ziad A ^d   Maiz, Hedi Ben ^c   Lacour, Bernard ^d   Mebazza, Abderraouf ^a  

^a LA RABTA HOSPITAL   (Tunisia)

^b HEDI CHAKER HOSPITAL   (Tunisia)

^c CHARLES NICOLLE HOSPITAL   (Tunisia)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

C reactive protein; Cardiovascular disease; End stage renal disease; Fibrinogen; Homocysteine; Lipoprotein (a)

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CHOLESTEROL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMODIALYSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOALBUMINEMIA; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PROTEIN BLOOD LEVEL; RISK FACTOR; SMOKING; TUNISIA;

ADULT; AGE FACTORS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; FEMALE; FIBRINOGEN; FLUORESCENCE POLARIZATION IMMUNOASSAY; HOMOCYSTEINE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; LIPOPROTEIN(A); MALE; RISK FACTORS; TUNISIA;

EID: 4344683267     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. US Renal Data System, USRDS. Annual Data Report; National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md, April 1996.
2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J kidney Dis 1998; 32:112-9.
3. Parfrey PS, Harnett JD. Long term cardiac morbidity and mortality during dialysis therapy. Adv Nephrol 1994; 23:311-30.
4. Levey AS, Beto JA, Coronado BE, Eknoayan G, Foley RN, Kasiske BL. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998; 32:853-906.
5. Jacobsen DW. Homocysteine and vitamins in cardiovascular disease. Clin Chem 1998; 44:1833-43.
6. Irish A. Cardiovascular disease, fibrinogen and acute phase response: associations with lipids and blood pressure in patients with chronic renal disease. Atherosclerosis 1998; 137:133-9.
7. Ikizler TA, Wingard RL, Harvell J, Shyr Y, Hakim RM. Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study. Kidney Int 1999; 55:1945-51.
8. de Ferranti S, Rifai N. C-reactive protein and cardiovascular disease: a review of risk prediction and interventions. Clin Chim Acta 2002; 317:1-15.
9. Eikelboom JW, Hankey GJ. Associations of homocysteine, C-reactive protein and cardiovascular disease in patients with renal disease. Curr Opin Nephrol Hypertens 2001; 10:377-83.
10. Bergstrom J, Lindholm B. Malnutrition, cardiac disease and mortality: an integrated point of view. Am J Kidney Dis 1998; 32:834-41.
11. Farmer JA, Torre-Amione G. Atherosclerosis and inflammation. Curr Atheroscler Rep 2002; 4:92-8.
12. Bostom AG, Lathraup L. Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997; 52:10-20.
13. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW, Robinson K, Dennis VW. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end stage renal disease. Circulation 1998; 97:138-41.
14. Manns BJ, Burgess ED, Hyndman ME, Parsons HG, Schaefer JP, Scott-Douglas NW. Hyperhomocysteinemia and the prevalence of atherosclertic vascular disease in patients with end-stage renal disease. Am J Kidney Dis 1999; 34:669-77.
15. Stenvinkel P, Heimberger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55:1899-911.
16. Massy ZA. Importance of homocysteine, lipoprotein [a] and non-classical cardiovascular risk factors [fibrinogen and ad-vanced glycation end products] for atherogenesis in uremic patients. Nephrol Dial Transplant 2000; 15 [suppl] 51:81-91.
17. Zimmerman J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55:648-58.
18. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
19. Wanner C, Quaschning T, Dyslipidemia and renal disease: pathogenesis and clinical consequences. Curr Opin Nephrol Hypertens 2001; 10:195-201.
20. Massy ZA, Kasiske BL. Hyperlipidemia and its management in renal disease. case. Curr Opin Nephrol Hypertens 1996; 5:141-6.
21. Jungers P, Massy ZA, Khoa TN, Fumeron C, Labrunie M, Lacour B, Descamps-Latscha B, Man N. Incidence and risk factors for atherosclerotic cardiovascular accidents in predialysis chronic renal failure? Nephrol Dial Transplant 1997; 12:2597-602.
22. Kronenberg F, Utermann G, Dieplinger H. Lipoprotein[a] in renal disease. Am J Kidney Dis 1996; 27:1-25.
23. Sechi LA, Zingaro L, De Carli S, Sechi G, Catena C, Falleti E, Dell'Anna E, Bartoli E. Increased serum lipoprotein[a] levels in patients with early renal failure. Ann Intern Med 1998; 129:457-61.
24. Diop ME, Viron B, Bailleul S, Lefevre G, Fessi H, Mory J, Etienne J, Coudere R. Lp[al is increased in hemodialysis patients according to the type of dialysis membrane: a two-year fellow-up study. Clin Nephrol 2000; 54:210-7.
25. Moliterno DJ, Jokinen EV, Miserez AR, Lange RA, Willard JE, Borerwinkle E, Hillis LD. No association between plasma lipo-protein[a] concentrations and presence or absence of coronary atherosclerosis in African-Americans. Arterioscler Thromb Vase Biol 1995; 15:850-5.
26. Cantin B, Gagnon F, Moorjani S, Despres JP, Lamarche B, Lupien PJ, Dagenais GR. Is lipoprotein [a] an independent risk factor for ischemic heart disease in men? The Quebec Cardio-vascular Study. J Am Coll Cardiol 1998; 31:519-25.
27. Tomura S, Nakamura Y, Doi M, Ando R, Ida T, Chida Y, Ootsuka S, Shinoda T, Yanagi H. Fibrinogen, coagulation factor VIL tissue plasminogen activator, plasminogen activitor inhibitor-1 and lipids as cardiovascular risk factors in chronic hemodialysis and CAPD, patients. Am J Kidney Dis 1996; 27:848-54.
28. Martinez M, Vaya A, Alvarino J, Barbera JL, Ramos D, Lopez A, Aznar J. Hemorheological alterations in patients with chronic renal failure. Effect of hemodialysis. Clin Hemoreol Microcirc, 1999; 21:1-6.
29. Koch M, Kutkuhn B, Trenkwalder E, Bach D, Grabensee B, Dieplinger H, Kronengerg F, Apolipoprotein B, fibrinogen, HDL cholesterol and apolipoprotein[a] phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol 1997; 8:1889-98.
30. Naruszewicz M, Klinke M, Dziewanowski K, Stanewicz A, Bukowska H. Homocysteine, fibrinogen, and lipoprotein [a] levels are simultaneously reduced in patients with chronic renal failure treated with folic acid, pyridoxine, and cyanocobalamin. Metabolism 2001; 50:131-4.
31. Boaz M, Matas Z, Biro A, Kadzir Z, Green M, Fainaru M, Smetana S. Comparison of haemostatic factors and serum ma-londialdehyde as predictive factors for cardiovascular disease in hemodialysis patients. Am J Kidney Dis 1999; 34:438-44.
32. Massy ZA, Chadefaux-Vekemans B, Chevalier A, Bader CA, Drueke TB, Legendre C, Lacour B, Kamoun P, Kreish H. Hyperhomocysteinemia: a significant risk factor for cardiovascular disease in renal transplant recipients. Nephrol Dialysis Trans-plant 1994; 9:1103-9.
33. Tremblay R, Bonnardeaux A, Geadah D, Busque L, Lebrun M, Wuimer D, Leblanc M. Hyperhomocysteinemia in hemodialysis patients: effects of 12-month supplementation with hydrosoluble vitamins. Kidney Int 2000; 58:851-8.
34. Woodside JV, Fogarty DG, Lightbody JH, Loughrey CM, Yarnell JW, Maxwell AP, Young IS. Homocysteine and B group vitamins in renal transplant patients. Clin Chim Acta 1999; 282: 157-66.
35. Bostom AG, Shemin D, Lapane KL, Nadeau MR, Sutherland P, Chan J, Rozen R, Yoburn D, Jacques PF, Selhub J, Rosenberg IH. Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis 1996; 123:1-2.
36. Suliman ME, Lindholm B, Barany P, Bergstrom J. Hyperhomocysteinemia in chronic renal failure patients: relation to nutritional status and cardiovascular disease. Clin Chem Lab Med 2001; 39:734-8.
37. Canada-USA [CANUSA] peritoneal dialysis study group. Adequacy dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. J Am Soc Nephrol 1996; 7: 198-207.
38. Kaysen GA. Biological basis of hypoalbuminemia in ESRD. J Am Soc Nephrol 1998; 9:2368-76.
39. Sezer S, Ozdemir FN, Akman B, Arat Z, Anaforoglu I, Haberal M. Predictors of serum albumin level in patients receiving continuous ambulatory peritoneal dialysis. Adv Perit Dial 2001; 17:210-4.
40. Qureshi AR, Alvestrand A, Danielsson A, Divino-Filho JC, Gutierrez A, Lindolm B, Bergstrom J. Factors predicting malnutrition in hemodialysis patients: a cross-sectional study. Kidney Int 1998; 53:773-82.
41. Kaysen GA, Dubin JA, Muller HG, Rosales LM, Levin NW. The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. The HEMO Study Group. Kidney Int 2000; 58: 346-52.
42. Folsom AR, Ma J, Eckfeldt JH, Nieto FJ, Metcalf PA, Barnes RW. Low serum albumin: association with diabetes mellitus and other cardiovascular risk factors but not with prevalent cardiovascular disease or carotid artery intima-media thickness. Ann Epidemiol 1995; 5:186-91.
43. Panichi V, Migliori M, De Pietro S, Taccola D, Bianchi AN, Norpoth M, Metelli MR, Giovannini L, Tetta C, Palla R. C-Reactive protein in patients with chronic failure diseases. Ren Fail 2001; 23:551-62.
44. Their M, Ronnholm K, Sairanen H, Holmberg C, Jalanko H. Serum C-reactive protein in pediatric kidney and liver transplant patients. Pediatr Transplant 2002; 6:153-60.
45. Reek C, Conrad S, Tenschert W, Huland H. Do serum C-reactive protein measurements help to discriminate episodes of renal dysfunction in patients after renal transplantation? Clin Chim Acta 2001; 310:57-61.
46. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Fermo I, Foca A, Paroni R, Malatino LS. Inflammation is associated with carotid atherosclerosis in dialysis patients. J Hypertens 2000; 18: 1207-13.
47. Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? Kidney Int 2001; 59:407-14.